drugset / Trial / NCT01062399

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT01062399

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Giving everolimus together with temozolomide and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus when given together with temozolomide and radiation therapy and to see how well it works in treating patients with newly diagnosed glioblastoma multiforme.

Timeline

Start
2010-12
Primary completion
2016-06
Completion
2022-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 2.5 mg Oral
Subject Everolimus Small molecule 5 mg Oral
Subject Everolimus Small molecule 10 mg Oral
Background Temozolomide Small molecule 75 mg/m2 Oral
Background Temozolomide Small molecule 150 mg/m2 Oral
Background Temozolomide Small molecule 200 mg/m2 Oral